IgA nephropathy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 20: Line 20:


{{SK}} IgA nephritis; IgAN; Berger's disease; synpharyngitic glomerulonephritis
{{SK}} IgA nephritis; IgAN; Berger's disease; synpharyngitic glomerulonephritis
== [[IgA nephropathy overview|Overview]] ==


== [[IgA nephropathy historical perspective|Historical Perspective]] ==
== [[IgA nephropathy classification|Classification]] ==
== [[IgA nephropathy pathophysiology|Pathophysiology]] ==
== [[IgA nephropathy causes|Causes]] ==
== [[IgA nephropathy differential diagnosis|Differentiating IgA nephropathy from other Diseases]] ==
== [[IgA nephropathy epidemiology and demographics|Epidemiology and Demographics]] ==
== [[IgA nephropathy risk factors|Risk Factors]] ==
==[[IgA nephropathy screening|Screening]]==
== [[IgA nephropathy natural history|Natural History, Complications and Prognosis]] ==
== Diagnosis ==
[[IgA nephropathy symptoms|History and Symptoms]] | [[IgA nephropathy physical examination|Physical Examination]] | [[IgA nephropathy laboratory findings|Laboratory Findings]] | [[IgA nephropathy electrocardiogram|Electrocardiogram]] | [[IgA nephropathy chest x ray|Chest X Ray]] | [[IgA nephropathy CT|CT]] | [[IgA nephropathy MRI|MRI]] | [[IgA nephropathy echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[IgA nephropathy other imaging findings|Other Imaging Findings]] | [[IgA nephropathy other diagnostic studies|Other Diagnostic Studies]]
== Treatment ==
[[IgA nephropathy medical therapy|Medical Therapy]] | [[IgA nephropathy surgery|Surgery]] | [[IgA nephropathy primary prevention|Primary Prevention]] | [[IgA nephropathy secondary prevention|Secondary Prevention]] | [[IgA nephropathy tertiary prevention|Tertiary Prevention]] | [[IgA nephropathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[IgA nephropathy future or investigational therapies|Future or Investigational Therapies]]
==Case Studies==
[[IgA nephropathy case study one|Case #1]]
{{Nephrology}}
{{Nephrology}}



Revision as of 22:37, 27 September 2012

For patient information click here Template:DiseaseDisorder infobox

IgA nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating IgA nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

IgA nephropathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of IgA nephropathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on IgA nephropathy

CDC on IgA nephropathy

IgA nephropathy in the news

Blogs on IgA nephropathy

Directions to Hospitals Treating IgA nephropathy

Risk calculators and risk factors for IgA nephropathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Synonyms and keywords: IgA nephritis; IgAN; Berger's disease; synpharyngitic glomerulonephritis

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating IgA nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Tertiary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1 Template:Nephrology

de:IgA-Nephritis sv:IgA-nefrit


Template:WikiDoc Sources